Knee osteoarthritis (OA) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Knee osteoarthritis (OA) is a common progressive multifactorial joint disease characterised by chronic pain and functional disability. Knee OA accounts for almost four-fifths of the burden of OA worldwide and increases with obesity and age. Knee OA is incurable except knee arthroplasty, which is considered an effective treatment at an advanced stage of the disease; but is responsible for substantial health costs. Pain results in the affected joint, including thickening of the joint capsule and the formation of osteophytes. Overall, 43.3% reported having pain, aching, or stiffness in a knee joint on most days.15 Reports of pain increased with age (45 to 54 years, 34.2%; 75 years and older, 56.6%).

·       The overall global prevalence of knee OA was 16.0% in individuals aged 15 and over and was 23.2% in individuals aged 40 and over.

·       Presently, there are no drugs approved that can prevent, stop, or even restrain the progression of OA. Moreover, the available medications that promise to mitigate the pain of OA have several risk/benefit considerations. Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with a clinically relevant 50 –100% increase in the risk of myocardial infarction or cardiovascular death.

The competitive landscape of Knee osteoarthritis (OA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Knee osteoarthritis (OA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Knee osteoarthritis (OA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Knee osteoarthritis (OA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          LNA043            Novartis Pharmaceuticals          Phase 2

2          GXCPC1           Gwo Xi Stem Cell Applied Technology Co., Ltd.            Phase 2

3          MM-II   Moebius Medical Ltd.     Phase 2

4          SMUP-IA-01     Medipost Co Ltd.           Phase 1

5          PK101  PMG Pharm Co., Ltd     Phase 3

6          CNTX-4975-05  Centrexion Therapeutics            Phase 1

7          SM04690          Biosplice Therapeutics, Inc.       Phase 2

8          ABT-981           AbbVie  Phase 2

9          YH23537          Yuhan Corporation        Phase 2

10        UBX0101          Unity Biotechnology, Inc.           Phase 1

Continued